Search

Your search keyword '"Immunologic Factors pharmacokinetics"' showing total 3 results
Start Over Descriptor "Immunologic Factors pharmacokinetics" Region united states
3 results on '"Immunologic Factors pharmacokinetics"'

1. IgG replacement therapy, no size fits all.

Author

Bonilla FA

Subjects
Area Under Curve, Biological Availability, Brazil, Europe, Humans, Immunoglobulin G blood, Immunoglobulins administration & dosage, Immunoglobulins therapeutic use, Immunoglobulins, Intravenous administration & dosage, Immunoglobulins, Intravenous pharmacokinetics, Immunoglobulins, Intravenous therapeutic use, Immunologic Factors administration & dosage, Immunologic Factors pharmacokinetics, Immunologic Factors therapeutic use, Infusions, Subcutaneous, Pharmacokinetics, Therapeutic Equivalency, United States, United States Food and Drug Administration, Immunoglobulin G administration & dosage, Immunoglobulin G therapeutic use, Immunologic Deficiency Syndromes therapy
Published
2011
Full Text
View/download PDF

2. Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies.

Author

Berger M, Rojavin M, Kiessling P, and Zenker O

Subjects
Adolescent, Adult, Aged, Area Under Curve, Biological Availability, Body Mass Index, Brazil, Child, Europe, Female, Humans, Immunoglobulin G blood, Immunoglobulins administration & dosage, Immunoglobulins therapeutic use, Immunoglobulins, Intravenous administration & dosage, Immunoglobulins, Intravenous pharmacokinetics, Immunoglobulins, Intravenous therapeutic use, Immunologic Factors administration & dosage, Immunologic Factors pharmacokinetics, Immunologic Factors therapeutic use, Male, Middle Aged, Therapeutic Equivalency, United States, United States Food and Drug Administration, Young Adult, Immunoglobulin G administration & dosage, Immunoglobulin G therapeutic use, Immunologic Deficiency Syndromes therapy, Infusions, Subcutaneous, Pharmacokinetics
Abstract

Bioavailability and pharmacokinetics of subcutaneous IgG (SCIG) and intravenous IgG (IVIG) differ. It is not clear if and/or how the dose should be adjusted when switching from IVIG to SCIG. Area under the curve (AUC) of serum IgG versus time and trough level ratios (TLRs) on SCIG/IVIG were evaluated as guides for adjusting the dose. The mean dose adjustments required for non-inferior AUCs with 2 different SCIG preparations were 137% (± 12%) and 153% (± 16%). However, there were wide variations between adjustments required by different subjects, and in the resulting TLRs. In contrast, combined data from multiple studies allow estimation of the ratio of IgG levels with different dose adjustments, and of the steady state serum levels with different SCIG doses. When switching a patient from IVIG to SCIG, individualizing the dosage based on measured serum IgG levels and the clinical response is preferable to using mean pharmacokinetic parameters., (Copyright © 2011 Elsevier Inc. All rights reserved.)

Published
2011
Full Text
View/download PDF

3. Washout period for immune-modifying drugs before natalizumab therapy.

Author

Ilanjian H and Shane R

Subjects
Antibodies, Monoclonal adverse effects, Antibodies, Monoclonal therapeutic use, Antibodies, Monoclonal, Humanized, Drug Interactions, Humans, Immunologic Factors adverse effects, Immunologic Factors pharmacokinetics, Immunologic Factors therapeutic use, Immunosuppressive Agents pharmacokinetics, Leukoencephalopathy, Progressive Multifocal chemically induced, Metabolic Clearance Rate, Multiple Sclerosis drug therapy, Natalizumab, Risk Management, United States, Antibodies, Monoclonal administration & dosage, Immunologic Factors administration & dosage
Published
2008
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results